ContraVir Pharmaceuticals (NYSE:HEPA) Earns “Buy” Rating from Roth Capital

Roth Capital reissued their buy rating on shares of ContraVir Pharmaceuticals (NYSE:HEPA) in a report published on Thursday, Zacks.com reports.

Shares of HEPA traded up $0.18 during trading hours on Thursday, reaching $3.26. The stock had a trading volume of 131,974 shares.

ContraVir Pharmaceuticals (NYSE:HEPA) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($7.48) EPS for the quarter.

About ContraVir Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B.

Recommended Story: NASDAQ Stock Market Explained

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit